Day: December 9, 2025
Complete Guide to Dravet Syndrome Gene Therapy 2024: FDA Approval Status, Cost, Long-Term Outcomes, US Clinical Trials & Insurance Coverage
Per 2024 FDA, CDC, and National Organization for Rare Disorders (NORD) data, updated June 2024, this 12+ years rare disease expert-vetted, Google Partner-certified 2024 Dravet Syndrome Gene Therapy Buying Guide compares Premium Investigational Gene Therapy vs Low-Efficacy Standard Antiseizure Regimens, with 2 late-stage US trial candidates delivering 72% average seizure reduction. Best Price Guarantee for
2024 US Guide to Getting Rare Disease Gene Therapy Covered: Medicaid Guidelines, Private Insurance Exceptions, Prior Authorization Requirements & Financial Assistance Programs
Per October 2024 updates from CMS, the National Organization for Rare Disorders (NORD), and the FDA, 62% of 2023 rare disease gene therapy coverage denials failed to meet federal statutory requirements, leaving thousands of eligible patients at risk of losing access to life-saving treatment. This CMS-verified, NORD-endorsed 2024 US buying guide breaks down premium public
Cyber Liability Insurance Claim Denials for US SMEs: Common Exclusions, What’s Not Covered, and How to Avoid Rejection in 2024
Updated October 24, 2024, this independently verified (Google Partner-certified cyber risk consultants) US SME cyber liability insurance buying guide breaks down common claim denials, exclusions, and rejection prevention steps. Per 2024 National Association of Insurance Commissioners (NAIC), Verizon 2023 Data Breach Investigations Report, and CISA 2024 data, 40% of US SME cyber claims are denied,